GlobeNewswire: XOMA Corporation Contains the last 10 of 473 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T16:31:03ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/21/2850137/0/en/XOMA-Declares-Quarterly-Preferred-Stock-Dividends.html?f=22&fvtc=4&fvtv=5542XOMA Declares Quarterly Preferred Stock Dividends2024-03-21T11:30:00Z<![CDATA[EMERYVILLE, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock:]]>https://www.globenewswire.com/news-release/2024/03/19/2848966/0/en/XOMA-Announces-Calculation-of-Additional-Price-Per-Share-and-Extension-of-Expiration-Date-for-Tender-Offer-for-Kinnate-Biopharma-Inc.html?f=22&fvtc=4&fvtv=5542XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.2024-03-19T20:05:00Z<![CDATA[Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio]]>https://www.globenewswire.com/news-release/2024/03/08/2843058/0/en/XOMA-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Highlights-Recent-and-Upcoming-Events-Expected-to-Drive-Shareholder-Value.html?f=22&fvtc=4&fvtv=5542XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value2024-03-08T12:30:00Z<![CDATA[Raised up to $140 million of non-dilutive non-recourse capital through a royalty-backed loan related to VABYSMO® from funds managed by Blue Owl Capital]]>https://www.globenewswire.com/news-release/2024/02/28/2836848/0/en/XOMA-to-Present-at-Upcoming-Investor-Conferences-in-March.html?f=22&fvtc=4&fvtv=5542XOMA to Present at Upcoming Investor Conferences in March2024-02-28T12:30:00Z<![CDATA[EMERYVILLE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following March 2024 investor conferences:]]>https://www.globenewswire.com/news-release/2024/02/16/2830729/0/en/XOMA-Enters-into-Agreement-to-Acquire-Kinnate-Biopharma-for-Between-2-3352-and-2-5879-in-Cash-Per-Share-Plus-a-Contingent-Value-Right.html?f=22&fvtc=4&fvtv=5542XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right2024-02-16T13:00:00Z<![CDATA[Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio]]>https://www.globenewswire.com/news-release/2024/01/18/2811533/0/en/XOMA-Expands-its-Commercial-Royalty-and-Milestone-Portfolio-with-DSUVIA-Acquisition.html?f=22&fvtc=4&fvtv=5542XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition2024-01-18T13:30:00Z<![CDATA[XOMA provided an $8 million non-dilutive royalty capital solution to Talphera]]>https://www.globenewswire.com/news-release/2024/01/11/2808325/0/en/FDA-Acceptance-of-Zevra-s-Arimoclomol-NDA-Filing-for-Niemann-Pick-Disease-Type-C-NPC-Results-in-XOMA-Making-a-1-Million-Milestone-Payment-to-LadRx.html?f=22&fvtc=4&fvtv=5542FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx2024-01-11T21:05:00Z<![CDATA[FDA has acknowledged receipt of the resubmission and assigned a PDUFA target action date of June 21, 2024 FDA has acknowledged receipt of the resubmission and assigned a PDUFA target action date of June 21, 2024]]>https://www.globenewswire.com/news-release/2024/01/08/2805333/0/en/XOMA-Names-Owen-Hughes-as-Chief-Executive-Officer-and-Appoints-Jack-L-Wyszomierski-as-Chairman-of-the-Board-of-Directors.html?f=22&fvtc=4&fvtv=5542XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors2024-01-08T12:30:00Z<![CDATA[EMERYVILLE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today the Board of Directors has named Owen Hughes as Chief Executive Officer and Jack L. Wyszomierski as Chairman of the Board. Mr. Hughes has served as XOMA’s Executive Chairman and Interim Chief Executive Officer since January 1, 2023.]]>https://www.globenewswire.com/news-release/2024/01/02/2802594/0/en/XOMA-Announces-Stock-Repurchase-Program-of-up-to-50-Million.html?f=22&fvtc=4&fvtv=5542XOMA Announces Stock Repurchase Program of up to $50 Million2024-01-02T12:30:00Z<![CDATA[Balanced capital allocation strategy looks to return capital to shareholders while continuing to invest in royalty and milestone acquisitions that will drive total shareholder return Balanced capital allocation strategy looks to return capital to shareholders while continuing to invest in royalty and milestone acquisitions that will drive total shareholder return]]>https://www.globenewswire.com/news-release/2023/12/20/2799168/0/en/XOMA-Declares-Quarterly-Preferred-Stock-Dividends.html?f=22&fvtc=4&fvtv=5542XOMA Declares Quarterly Preferred Stock Dividends2023-12-20T12:30:00Z<![CDATA[EMERYVILLE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock:]]>